BlinkRx

Interesting data points from Phathom Pharmaceuticals' impressive Q3 earnings results: Cash prescriptions for VOQUEZNA grew 38% quarter-over-quarter, reaching 77,000 fills. In April, the company enabled Medicare patients to access the medication through cash-pay via BlinkRx — a population that previously had no coverage pathway. The company noted that Q3's cash prescription growth "includes the impact" of turning on this Medicare access. Total Q3 prescription volume: 221,000 total fills 144,000 covered prescriptions (23% growth QoQ) 77,000 cash prescriptions (38% growth QoQ) The takeaway: When you create an access pathway for patients who fall outside traditional coverage, prescription fills follow. At BlinkRx, cash-pay is one lever in our comprehensive platform. We work across the full spectrum of access and affordability barriers to increase fill rates for pharma clients and get patients the medications they need. https://lnkd.in/ep9RVN_N Investing.com

News: The U.S. Food and Drug Administration has approved Bayer's Lynkuet for easing hot flashes in menopausal women. The drug is a non-hormonal treatment designed to relieve moderate-to-severe vasomotor symptoms associated with menopause. We're proud to share that Bayer has partnered with us, and eligible patients may pay as little as $25 a month for this important therapy. https://lnkd.in/gpmfjRhr

Luke is exactly right. In this video, he tells us, "In 2025, 1 out of 5 prescriptions were abandoned." This is because the prescription journey is broken at every touchpoint: rejected claims, PA abandonment, pharmacy stock-outs, surprise costs at refill. Patients face barriers that are invisible with traditional data, and by the time you identify the drop-off, they're already gone. We've proven that pharma partners can increase fills per patient by 41% when they can see and control the entire prescription journey.

Geoffrey Chaiken, our Co-Founder and CEO, will join other top biotech and pharma CEOs, R&D heads, investors, and Longwood Healthcare Leaders at the upcoming Boston CEO meeting, for two days of discussion on the most important issues facing healthcare today. October 27-28, 2025 Mandarin Oriental, Boston We look forward to connecting with fellow leaders on patient-centric development, commercial success strategies, and transforming patient access. https://hubs.ly/Q03LNLP90

The past 25 years brought CRM systems, omnichannel engagement, and Next Best Action. Yet the core go-to-market model still relies on a 25-year-old claims data innovation. Time to modernize. Manufacturers need a platform that integrates real-time data. At BlinkRx, we offer two game-changing innovations: • Real-Time Access: Data delivered in real-time, not monthly or quarterly lags • Contribution Margin Data: Individual prescription profitability, not just volume Our Real-Time Rx Graph is a dynamic system capable of grouping data at any level, offering unprecedented visibility and actionability across sales, marketing, market access, and patient services. This represents a fundamental transformation: • From volume optimization to margin optimization • From quarterly adjustments to continuous improvement • From reactive analysis to proactive intervention By making real-time data foundational to their go-to-market strategy, today's innovators can create the next blockbuster with modern tools. Learn how to modernize your commercial data infrastructure in our white paper, Data Boom 2.0: https://hubs.ly/Q03KB17j0 Is your organization ready for the data revolution? #Pharma #PLMP #RealTimeData #Innovation

Traditional targeting focuses on high-volume prescribers, but our Real-Time Rx Graph shows contribution margin varies dramatically across HCPs. One client's top 1,400 physicians represented 2x the contribution margin versus volume-based targeting after accounting for patient support, channel fees, and PBM rebates. Get the complete framework in our white paper, Data Boom 2.0: https://hubs.ly/Q03J-Dqh0 #BlinkRx #DirectToPatient #PharmaTech #RealTimeData #PharmaInnovation #DigitalHealth #HealthcareInnovation

Most pharma brands still target prescribers by volume. But volume ≠ value. We found that if you prioritize prescribers based on their contribution margin rather than volume, you can double your contribution margin. The traditional model assumes: High-volume prescribers = high-value targets More scripts = more margin Bigger practices = bigger opportunity The reality our Real-Time Rx Graph shows: • Contribution margin varies wildly across prescribers • Patient support, channel fees, and PBM rebates dramatically impact profitability • Small practices can deliver higher margins than large ones When we rebuilt one client's target HCP list using real-time contribution margin data, their top 1,400 physicians represented 2x the contribution margin versus legacy volume-based methodologies. It's time to rethink how we define commercial success. Get the complete framework for transitioning from volume to margin-based targeting, including detailed case studies and implementation strategies, in our white paper Data Boom 2.0: The Power of Real-Time Data: https://lnkd.in/eehBB3Q5 If you want to double brand value, the easiest way is to target based on contribution margin instead of volume. #Pharma #CommercialStrategy #ROI #DataDriven

In a market this competitive, speed compounds. Acting on last quarter’s data is not enough. The leaders of tomorrow will act on today’s — and they’ll pull further ahead with every decision. Learn more: https://hubs.ly/Q03HySjT0 #Pharma #RealTimeData #Speed #CompetitiveAdvantage

Our Real-Time Rx Graph reveals insights about pharma targeting that traditional claims data completely misses. Across the BlinkRx platform, we see a 100% contribution margin difference between lowest and highest quartile scripts for the same brand. We also see almost no correlation between HCP size and contribution margin. What traditional claims data shows you: Total prescription volume by physician Practice size and specialty Market share trends (with quarterly delays) What the Real-Time Rx Graph reveals: Individual prescription contribution margins in real-time Patient support costs, channel fees, and PBM rebates per script True ROI of each commercial action, not just volume impact The result: When we created one client's target HCP list using the Real-Time Rx Graph, the top 1,400 physicians represented 2x the contribution margin versus legacy volume-based methodologies. This isn't just better targeting — it's a fundamental shift from volume optimization to margin optimization, enabled by real-time data feedback loops. Discover how the Real-Time Rx Graph works in our white paper Data Boom 2.0: The Power of Real-Time Data: https://hubs.ly/Q03HyJn00 Is your organization optimizing for volume or contribution margin? #Pharma #RealTimeData #ContributionMargin #DataDriven

Our research explores how data innovations continue to create systematic commercial advantages in pharma — now, at unprecedented speed. Over 25 years ago, Pfizer reshaped pharma commercialization by aggregating prescription claims data, while others relied on HCP publication lists. That shift in data strategy helped propel Lipitor from $3.8B to $12.9B in just seven years. Pfizer’s insight: Quarterly prescription volume data enabled a reach-and-frequency model that changed the industry. Today’s evolution: Real-time contribution margin data at the individual prescription level enables dynamic, prescription-level optimization. At BlinkRx, we've built on that legacy with the Real-Time Rx Graph — our dynamic system that delivers ecommerce-like insights through the Prescription Lifecycle Management Platform (PLMP). It’s a step change that empowers smarter, faster decisions. Then vs. now: Pfizer: Quarterly volume → Reach & frequency BlinkRx: Real-time margin → Rx-level optimization While breakthrough therapies like GLP-1s can thrive on market buzz, most therapies require the kind of systematized, data-enabled approach that made Lipitor a legend — now turbocharged by real-time precision. Discover the three systematic principles that drove Lipitor’s success and how they’re being reimagined in the era of real-time Rx data in our white paper: Data Boom 2.0: The Power of Real-Time Data (link in comments). How is your organization preparing for the real-time data revolution? #Pharma #RealTimeData #DataStrategy #Innovation